GlassScriptPhysician profile
Joerel Ramos
NPI 1043273071
$12,608.37
in general payments reported to CMS, 2019-2025
27 companies · $2,195 in 2025
The $2,195 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,733 · 2020: $1,166 · 2021: $1,932 · 2022: $1,769 · 2023: $1,716 · 2024: $2,098 · 2025: $2,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,008.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,024.72 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $1,869.10 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,486.27 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $1,052.90 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $752.15 | 2019-2024 | |
| Genzyme Corporation | $696.10 | 2019-2025 | |
| Genentech USA, INC. | $635.77 | 2019-2024 | Xolair |
| Insmed, INC. | $538.37 | 2019-2025 | Arikayce, Brinsupri |
| Electromed, INC. | $536.73 | 2019-2025 | Smartvest |
| Mallinckrodt Hospital Products INC. | $360.14 | 2020-2023 | Acthar |
| Sunovion Pharmaceuticals INC. | $309.44 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $252.24 | 2019-2023 | Opsumit |
| Baxter Healthcare | $234.93 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Philips North America LLC | $196.22 | 2019-2025 | Vest Therapy Und |
| Mylan Specialty L.P. | $150.70 | 2019-2024 | Yupelri |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $101.25 | 2025 | Yupelri |
| Mallinckrodt Enterprises LLC | $92.99 | 2019 | |
| Amgen INC. | $54.84 | 2024-2025 | Tezspire |
| Horizon Therapeutics Plc | $54.19 | 2023 | Krystexxa |
| Teva Pharmaceuticals USA, INC. | $45.14 | 2020 | |
| Paratek Pharmaceuticals, INC. | $43.70 | 2024 | Nuzyra |
| Fresenius USA Marketing, INC. | $24.62 | 2024 | Velphoro |
| Grifols USA, LLC | $21.48 | 2020 | |
| Merck Sharp & Dohme LLC | $21.26 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.86 | 2019 | |
| Hikma Pharmaceuticals USA | $17.64 | 2024 | Ryaltris |
| Circassia INC. | $15.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joerel Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.